Journal of Biomedical Science,
Год журнала:
2024,
Номер
31(1)
Опубликована: Авг. 13, 2024
Abstract
Gene
therapy
has
made
considerable
strides
in
recent
years.
More
than
4000
protein-coding
genes
have
been
implicated
more
6000
genetic
diseases;
next-generation
sequencing
dramatically
revolutionized
the
diagnosis
of
diseases.
Most
diseases
are
considered
very
rare
or
ultrarare,
defined
here
as
having
fewer
1:100,000
cases,
but
only
one
12
approved
gene
therapies
(excluding
RNA
therapies)
targets
an
ultrarare
disease.
This
article
explores
three
supplementation
approaches
suitable
for
various
diseases:
lentiviral
vector-modified
autologous
CD34
+
hematopoietic
stem
cell
transplantation,
systemic
delivery
adeno-associated
virus
(AAV)
vectors
to
liver,
and
local
AAV
cerebrospinal
fluid
brain.
Together
with
therapies,
we
propose
a
potential
business
model
these
therapies.
BMC Infectious Diseases,
Год журнала:
2024,
Номер
24(1)
Опубликована: Июнь 3, 2024
Abstract
Background
and
objective(s)
CRISPR-Cas
is
a
prokaryotic
adaptive
immune
system
that
protects
bacteria
archaea
against
mobile
genetic
elements
(MGEs)
such
as
bacteriophages
plasmids,
transposons.
In
this
study,
we
aimed
to
assess
the
prevalence
of
systems
their
association
with
antibiotic
resistance
in
one
most
challenging
bacterial
pathogens,
Klebsiella
pneumoniae
.
Materials
methods
A
total
105
K.
isolates
were
collected
from
various
clinical
infections.
Extended-spectrum
β-lactamases
(ESBLs)
phenotypically
detected
presence
ESBL,
aminoglycoside-modifying
enzymes
(AME),
subtype
genes
identified
using
PCR.
Moreover,
diversity
was
determined
by
enterobacterial
repetitive
intergenic
consensus
(ERIC)-PCR.
Results
Phenotypically,
41.9%
(44/105)
found
be
ESBL
producers.
significant
inverse
correlation
existed
between
I-E
system’s
production
isolates.
Additionally,
frequency
bla
CTX−M1
(3%),
CTX−M9
(12.1%),
SHV
(51.5%),
TEM
(33.3%),
well
some
AME
aac(3)-Iva
(21.2%)
ant(2’’)-Ia
(3%)
significantly
lower
comparison
CRISPR-negative
There
system.
Conclusion
The
correlated
antibiotic-resistant
gene
(ARGs).
had
than
Aquaculture and Fisheries,
Год журнала:
2024,
Номер
unknown
Опубликована: Июль 1, 2024
Aquaculture,
a
critical
sector
for
global
food
security,
faces
the
challenge
of
meeting
growing
demand
while
protecting
wild
fish
populations.
Gene
editing,
powerful
genetic
tool,
emerges
as
potential
solution.
By
modifying
key
genes
in
fish,
it
is
expected
to
rapidly
enhance
growth
rate,
disease
resistance,
and
other
economically
important
traits,
leading
increased
profitability,
sustainability,
competitiveness
industry.
This
review
navigates
complex
landscape
gene
editing
aquaculture,
exploring
successes,
challenges,
prospects
improved
productivity,
resilience.
We
provide
guidance
researchers
stakeholders
identifying
responsible
addressing
economic,
environmental,
regulatory,
ethical
considerations.
roadmap
paves
way
future
where
empowers
aquaculture
meet
needs
upholding
environmental
responsibility.
Biotechnology Journal,
Год журнала:
2024,
Номер
19(2)
Опубликована: Фев. 1, 2024
World's
population
is
elevating
at
an
alarming
rate
thus,
the
rising
demands
of
producing
crops
with
better
adaptability
to
biotic
and
abiotic
stresses,
superior
nutritional
as
well
morphological
qualities,
generation
high-yielding
varieties
have
led
encourage
development
new
plant
breeding
technologies.
The
availability
easy
accessibility
genome
sequences
for
a
number
crop
plants
various
editing
technologies
such
zinc
finger
nucleases
(ZFNs),
transcription
activator-like
effector
(TALENs)
has
opened
up
possibilities
develop
desirable
traits.
However,
these
approaches
limitation
being
more
expensive
having
complex
steps
time-consuming.
CRISPR/Cas
system
been
intensively
studied
allowing
versatile
target-specific
modifications
that
fruitfully
aid
in
novel
varieties.
It
advanced
promising
technology
potential
meet
hunger
needs
contribute
food
production
ever-growing
human
population.
This
review
summarizes
usage
tool
targeted
improvement
stress
resistance,
yield,
quality
traits
desired
plants.
Journal of Biomedical Science,
Год журнала:
2024,
Номер
31(1)
Опубликована: Авг. 13, 2024
Abstract
Gene
therapy
has
made
considerable
strides
in
recent
years.
More
than
4000
protein-coding
genes
have
been
implicated
more
6000
genetic
diseases;
next-generation
sequencing
dramatically
revolutionized
the
diagnosis
of
diseases.
Most
diseases
are
considered
very
rare
or
ultrarare,
defined
here
as
having
fewer
1:100,000
cases,
but
only
one
12
approved
gene
therapies
(excluding
RNA
therapies)
targets
an
ultrarare
disease.
This
article
explores
three
supplementation
approaches
suitable
for
various
diseases:
lentiviral
vector-modified
autologous
CD34
+
hematopoietic
stem
cell
transplantation,
systemic
delivery
adeno-associated
virus
(AAV)
vectors
to
liver,
and
local
AAV
cerebrospinal
fluid
brain.
Together
with
therapies,
we
propose
a
potential
business
model
these
therapies.
